secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001171843-23-006794
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q3 revenue $25.4M (-6% YoY); adjusted EBITDA margin 8.9%
---------------------------------------------------------------------------

- Q3 2023 revenues $25.4M vs $26.9M prior year; gross margin improved to 58.1% from 45.2%.
- GAAP net loss $1.2M ($0.03/share); adjusted EPS $0.01; adjusted EBITDA $2.2M (8.9% margin).
- Operating cash flow $4.4M; debt reduced $2.8M in Q3, total debt $38.7M.
- Updated FY2023 guidance: revenue approx flat YoY, gross margin ~60%, adjusted EBITDA margin 13%-14%.
- Asia headwinds and $1.3M revenue impact from discontinued products; North America revenue grew.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/0001171843-23-006794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184323006794/f8k_110323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer